Printing Digital Labels - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Printing Digital Labels
Going digital can produce high-quality, full-color labels at potentially lower cost.


Pharmaceutical Technology


As the January 1, 2009 deadline approaches for compliance with California's pedigree law, which requires drugs shipped to distributors to carry a unique identifier at the item level to support an electronic track-and-trace record keeping system, some wholesalers and drugmakers view RFID tagging at the item and case level as the ideal data carrier because information can be captured from the tags without the reader being in the line of sight of the packages. For drugmakers that don't have the RFID infrastructure in place, particularly for tagging at the item level, digitally printed two-dimensional (2D) barcodes can provide the unique identifier.

Options include printing a serialized 2D barcode or electronic product code number on the item label or on a medallion label that is applied separately to the item. Information about the item codes is then captured and written to an RFID case tag to link parent/child information. If RFID case tagging is not available, the item-level information can be captured and incorporated into a 2D code that is digitally printed on the case label so information about the contents of the case travels with it.

Several companies are working together to provide the hardware and software necessary for a pedigree process based on 2D barcodes.

Hallie Forcinio is Pharmaceutical Technology's Packaging Forum editor, 4708 Morningside Drive, Cleveland, OH 44109, tel. 216.351.5824, fax 216.351.5684,
.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here